- Home
- WKEY vs IMAB Comparison
WKEY vs IMAB Comparison
Compare WKEY & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WKEY
- IMAB
- Stock Information
- Founded
- WKEY 1999
- IMAB 2014
- Country
- WKEY Switzerland
- IMAB United States
- Employees
- WKEY N/A
- IMAB N/A
- Industry
- WKEY EDP Services
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- WKEY Technology
- IMAB Health Care
- Exchange
- WKEY Nasdaq
- IMAB Nasdaq
- Market Cap
- WKEY 78.1M
- IMAB 73.9M
- IPO Year
- WKEY N/A
- IMAB 2020
- Fundamental
- Price
- WKEY $6.41
- IMAB $2.49
- Analyst Decision
- WKEY Strong Buy
- IMAB Strong Buy
- Analyst Count
- WKEY 1
- IMAB 2
- Target Price
- WKEY $4.00
- IMAB $5.50
- AVG Volume (30 Days)
- WKEY 245.2K
- IMAB 944.0K
- Earning Date
- WKEY 06-24-2025
- IMAB 05-15-2025
- Dividend Yield
- WKEY N/A
- IMAB N/A
- EPS Growth
- WKEY N/A
- IMAB N/A
- EPS
- WKEY N/A
- IMAB N/A
- Revenue
- WKEY $11,875,000.00
- IMAB N/A
- Revenue This Year
- WKEY $18.18
- IMAB N/A
- Revenue Next Year
- WKEY $112.51
- IMAB N/A
- P/E Ratio
- WKEY N/A
- IMAB N/A
- Revenue Growth
- WKEY N/A
- IMAB N/A
- 52 Week Low
- WKEY $1.61
- IMAB $0.60
- 52 Week High
- WKEY $14.00
- IMAB $3.08
- Technical
- Relative Strength Index (RSI)
- WKEY 52.16
- IMAB 73.50
- Support Level
- WKEY $6.12
- IMAB $2.37
- Resistance Level
- WKEY $8.11
- IMAB $3.08
- Average True Range (ATR)
- WKEY 0.61
- IMAB 0.35
- MACD
- WKEY -0.08
- IMAB 0.10
- Stochastic Oscillator
- WKEY 24.44
- IMAB 71.94
About WKEY WISeKey International Holding Ltd
WISeKey International Holding Ltd is a cybersecurity company focused on delivering integrated security solutions for the Internet of Things and digital identity ecosystems. It integrates secure semiconductors, cybersecurity software, and a globally recognized Root of Trust (RoT) into products and services that protect users, devices, data and transactions in the internet-connected world. It has two business segments. The IoT segment, which is the key revenue driver, generates revenue from the sale of semiconductor's secure chips. The mPKI segment generates revenues from Digital Certificates, It derives maximum revenue from IoT segment.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).